placebo plus docetaxel; BIBF 1120 plus docetaxel
Проводит Boehringer Ingelheim
Страница компанииMulticentre, Randomised, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Docetaxel Therapy Compared to Placebo Plus Standard Docetaxel Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell Lung Cancer After Failure of First Line Chemotherapy
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT00805194/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
- Исследование завершено, новых участников не набирают.
- Возраст участников: от 18 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 1314 чел. во всех странах исследования.
- Центров в реестре: 15 в 12 городах. Список — ниже на странице.
- Плановая дата окончания (11.2017) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Главное из критериев
- Состояние пациента (ECOG)0–1
- Предшествующее лечениепосле предшествующей терапии (рецидив или прогрессия)
- Стадияметастатическая (IV), местно-распространённая (III)
- Метастазы в головной мозгактивные — не включают
- ИнфекцииВИЧ, гепатит B или C упомянуты в критериях невключения
Выбрано из текста реестра автоматически, по правилам — без ИИ. Решение об участии принимает врач центра по полному протоколу.
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 7 · невключение: 34
Критерии включения
- male or female patient aged 18 years or older;
- histologically or cytologically confirmed, locally advanced and/or metastatic NSCLC of stage IIIB or IV or recurrent NSCLC;
- relapse or failure of one first line prior chemotherapy;
- at least one target tumour lesion that has not been irradiated within the past three months and that can accurately be measured ;
- life expectancy of at least three months;
- Eastern Cooperative Oncology group (ECOG) score of 0 or 1;
- patient has given written informed consent
Критерии невключения
- more than one prior chemotherapy regimen for advanced and/or metastatic or recurrent NSCLC;
- more than one chemotherapy treatment regimen (either neoadjuvant or adjuvant or neoadjuvant plus adjuvant) prior to first line chemotherapy;
- previous therapy with other VEGFR inhibitors (other than bevacizumab) or docetaxel for treatment of NSCLC;
- persistence of clinically relevant therapy related toxicities from previous chemotherapy and/or radiotherapy;
- treatment with other investigational drugs or other anti-cancer therapy or treatment in another clinical trial within the past four weeks before start of - therapy or concomitantly with this trial ;
- radiotherapy (except extremities and brain) within the past three months prior to baseline imaging;
- active brain metastases or leptomeningeal disease;
- radiographic evidence of cavitary or necrotic tumours;
- centrally located tumours with radiographic evidence (CT or MRI) of local invasion of major blood vessels;
- history of clinically significant haemoptysis within the past 3 months;
- therapeutic anticoagulation (except low dose heparin) or antiplatelet therapy;
- history of major thrombotic or clinically relevant major bleeding event in the past 6 months;
- known inherited predisposition to bleeding or thrombosis;
- significant cardiovascular diseases ;
- inadequate safety laboratory parameters;
- significant weight loss (> 10 %) within the past 6 weeks;
- current peripheral neuropathy greater than CTCAE grade 2 except due to trauma;
- preexisting ascites and/or clinically significant pleural effusion;
- major injuries and/or surgery within the past ten days prior to randomisation with incomplete wound healing;
- serious infections requiring systemic antibiotic therapy;
- decompensated diabetes mellitus or other contraindication to high dose corticosteroid therapy;
- gastrointestinal disorders or abnormalities that would interfere with absorption of the study drug;
- active or chronic hepatitis C and/or B infection;
- serious illness or concomitant non-oncological disease or laboratory abnormality that may increase the risk associated with study participation or study drug administration;
- patients who are sexually active and unwilling to use a medically acceptable method of contraception during the trial and for at least twelve months after end of active therapy;
- pregnancy or breast feeding;
- psychological, familial, sociological or geographical factors potentially hampering compliance with the study protocol and follow-up schedule;
- patients unable to comply with the protocol;
- active alcohol or drug abuse;
- other malignancy within the past three years other than basal cell skin cancer, or carcinoma in situ of the cervix;
- any contraindications for therapy with docetaxel;
- history of severe hypersensitivity reactions to docetaxel or other drugs formulated with polysorbate 80 (Tween 80);
- hypersensitivity to BIBF 1120 and/or the excipients of the trial drugs;
- hypersensitivity to contrast media
Источник: ClinicalTrials.gov, NCT00805194 · запись обновлена в реестре 5 декабря 2018.
Дизайн и результаты
Что измеряют — первичные конечные точки (1), вторичных — 13
- Progression Free Survival (PFS) as Assessed by Central Independent Review — From randomisation until cut-off date 2 November 2010 (when 713 PFS events were observed)
Цель исследования
The present trial will be performed to evaluate whether BIBF 1120 in combination with standard therapy of docetaxel in patients with stage IIIB/IV or recurrent NSCLC is more effective as compared to placebo in combination with standard therapy of docetaxel. A secondary aim is to obtain safety information as well as information on quality of life of patients treated with BIBF 1120 in combination to standard therapy with docetaxel. In addition, blood will be collected for pharmacokinetic analysis.
Где проходит
15 центров в 12 городахОткуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT00805194 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.